ScreenerHero

ZTS Zoetis Inc.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · zoetis.com
71.55USD+0.31%Mkt Cap: 29.57B $P/E: 11.77

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the ani…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1
HLUN-B
H. Lundbeck A/S
$6.51BUSDP/E 11.5

Key Statistics

Company
Market Cap29.57B USD
Enterprise Value37.05B USD
Revenue (TTM)9.53B USD
Gross Profit6.80B USD
Net Income (TTM)2.67B USD
Revenue/Share22.14 USD
Last Price71.55 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)11.77
P/E (Forward)10.90
PEG6.65
EV/EBITDA9.11
EV/Revenue3.89
P/S3.09
P/B9.10
EPS (TTM)6.08
EPS (Forward)6.54
52W Range
68.773% of range148.30
52W High148.30 USD
52W Low68.77 USD
Profitability
Gross Margin71.84%
Oper. Margin40.72%
EBITDA Margin42.69%
Profit Margin28.23%
ROE80.25%
ROA17.28%
Growth
Revenue Growth-0.20%
Earnings Growth1.20%
Cash Flow & Leverage
Operating CF2.90B USD
CapEx (TTM)621.00M USD
FCF Margin21.18%
FCF Yield6.82%
Net Debt7.58B USD
Net Debt/EBITDA1.86
Balance Sheet
Debt/Equity2.77
Current Ratio3.08
Quick Ratio1.57
Book Value/Sh7.84 USD
Cash/Share4.06 USD
Dividends
Fwd Div Rate2.12 USD
Trail. Div Rate2.06 USD
Div. Yield2.97%
5Y Avg Yield0.91%
Payout Ratio33.88%
Ex-Div DateJul 20, 2026
Pay DateSep 1, 2026
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)96.00 USD
Upside (mean)+34.2%
Target Range80.00 USD – 155.00 USD
80.00+34.2% to mean155.00
# Analysts14
Ownership
Shares Out.413.22M
Float412.37M
Insiders0.16%
Institutions100.38%
Short Interest
Short Ratio3.8d
Short % Float4.76%
Short % Out.4.21%
Shares Short17.39M
Short (prev mo.)16.78M
Technical
SMA 5074.32 (-3.7%)
SMA 20098.09 (-27.1%)
Beta0.74
S&P 52W Chg15.78%
Avg Vol (30d)4.42M
Avg Vol (10d)4.13M
Technical Indicators
RSI (14)46.6
MACD-1.0597
MACD Signal-1.2005
MACD Hist.+0.1409
BB Upper74.27 USD
BB Middle71.61 USD
BB Lower68.94 USD
BB Width7.44%
ATR (14)1.836 USD
Vol Ratio (20d)0.87x